STOCK TITAN

Healthcare Triangle Takes Bold Step toward AI-Driven Future with the Signing of a Non-Binding LOI for the Acquisition of Teyame.AI, which is on track to generate $34M in Revenue for fiscal year 2025 and would create for Healthcare Triangle a Next-Generation Global Customer Engagement Platform

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

Healthcare Triangle (Nasdaq: HCTI) signed a non-binding Letter of Intent to acquire assets of Spain-based Teyame.AI, an AI-driven omnichannel customer experience platform. Based on information received, Teyame is expected to generate approximately $34 million in revenue and $4.2 million in EBITDA for fiscal 2025. The combination aims to create a global, AI-powered patient engagement platform by integrating Teyame's Agentic Gen AI, multilingual automation, and analytics with HCTI's clinical systems and QuantumNexis products.

Anticipated impacts include expanded international reach (Europe, LATAM, MENA, APAC), cross-selling into HCTI's hospital and clinic network, enhanced digital mental health workflows, and tighter front-end to back-end clinical integration. The LOI remains non-binding and subject to completion.

Healthcare Triangle (Nasdaq: HCTI) ha firmato una lettera d'intento non vincolante per acquisire asset di Teyame.AI, una piattaforma omnicanale di esperienza del cliente guidata dall'AI. Secondo le informazioni disponibili, Teyame dovrebbe generare circa $34 milioni di ricavi e $4,2 milioni di EBITDA per l'esercizio 2025. L'integrazione mira a creare una piattaforma globale di coinvolgimento dei pazienti alimentata dall'AI, combinando l'Agentic Gen AI di Teyame, l'automazione multilingue e l'analisi con i sistemi clinici di HCTI e i prodotti QuantumNexis.

Implicazioni previste includono una maggiore presenza internazionale (Europa, LATAM, MENA, APAC), opportunità di cross-selling all'interno della rete di ospedali e cliniche di HCTI, miglioramenti nei flussi di lavoro digitali di salute mentale e una maggiore integrazione tra front-end e back-end clinici. La LOI rimane non vincolante e soggetta al completamento.

Healthcare Triangle (Nasdaq: HCTI) firmó una Carta de Intención no vinculante para adquirir activos de Teyame.AI, una plataforma omnicanal de experiencia del cliente impulsada por IA. Según la información recibida, se espera que Teyame genere aproximadamente $34 millones de ingresos y $4,2 millones de EBITDA para el año fiscal 2025. La combinación tiene como objetivo crear una plataforma global de compromiso del paciente impulsada por IA al integrar el Gen AI Agentic de Teyame, la automatización multilingüe y análisis con los sistemas clínicos de HCTI y los productos QuantumNexis.

Efectos anticipados incluyen una mayor presencia internacional (Europa, LATAM, MENA, APAC), ventas cruzadas en la red de hospitales y clínicas de HCTI, mejoras en los flujos de trabajo de salud mental digital y una integración más estrecha de front-end a back-end clínico. La LOI sigue siendo no vinculante y sujeta a su finalización.

Healthcare Triangle (Nasdaq: HCTI)는 스페인 기반의 Teyame.AI 자산을 인수하기 위한 구속력 없는 양해각서(Letter of Intent)를 체결했습니다. Teyame은 AI 기반의 옴니채널 고객 경험 플랫폼입니다. 수신된 정보에 따르면 Teyame은 2025 회계연도에 약 $34 Millionen의 매출과 $4,2 Millionen의 EBITDA를 창출할 것으로 예상됩니다. 이 합병은 Teyame의 Agentic Gen AI, 다국어 자동화 및 분석 기능을 HCTI의 임상 시스템 및 QuantumNexis 제품과 통합하여 글로벌 AI 기반 환자 참여 플랫폼을 구축하는 것을 목표로 합니다.

예상 영향은 국제적 도달 범위 확대(유럽, LATAM, MENA, APAC), HCTI의 병원 및 클리닉 네트워크에 대한 교차 판매, 디지털 정신건강 워크플로우의 개선, 프런트 엔드에서 백 엔드 임상 통합에 대한 강화 등을 포함합니다. LOI는 비구속적이며 체결 완료를 전제로 합니다.

Healthcare Triangle (Nasdaq: HCTI) a signé une lettre d'intention non contraignante pour acquérir les actifs de Teyame.AI, une plateforme omnicanale d'expérience client pilotée par l'IA, basée en Espagne. Selon les informations reçues, Teyame devrait générer environ $34 millions de revenus et $4,2 millions d'EBITDA pour l'exercice 2025. Cette combinaison vise à créer une plateforme mondiale d'engagement des patients alimentée par l'IA en intégrant l'Agentic Gen AI de Teyame, l'automatisation multilingue et l'analytique avec les systèmes cliniques de HCTI et les produits QuantumNexis.

Impacts anticipés incluent une portée internationale élargie (Europe, LATAM, MENA, APAC), des ventes croisées dans le réseau hospitalier et clinique de HCTI, l'amélioration des flux de travail numériques en santé mentale et une meilleure intégration du front-end au back-end clinique. La LOI demeure non contraignante et soumise à l'achèvement.

Healthcare Triangle (Nasdaq: HCTI) hat eine unverbindliche Absichtserklärung zum Erwerb von Vermögenswerten von Teyame.AI, einer KI-gesteuerten Omnichannel-Kundenerfahrungsplattform, unterzeichnet. Nach verfügbaren Informationen wird erwartet, dass Teyame im Geschäftsjahr 2025 ca. $34 Millionen Umsatz und $4,2 Millionen EBITDA erwirtschaftet. Die Fusion zielt darauf ab, eine globale, KI-gestützte Plattform für Patienteneinbindung zu schaffen, indem Teyames Agentic Gen AI, mehrsprachige Automatisierung und Analytik mit den klinischen Systemen von HCTI und den QuantumNexis-Produkten integriert werden.

Erwartete Auswirkungen umfassen eine erweiterte internationale Reichweite (Europa, LATAM, MENA, APAC), Cross-Selling in HCTIs Krankenhaus- und Kliniknetzwerk, verbesserte digitale Mental-Health-Workflows und eine engere Front-End- zu Back-End-klinische Integration. Die LOI bleibt unverbindlich und unterliegt der Genehmigung.

Healthcare Triangle (ناسداك: HCTI) وقّع على خطاب نوايا غير ملزم للاستحواذ على أصول Teyame.AI، وهي منصة تجربة عميل omnichannel مدفوعة بالذكاء الاصطناعي ومقرها في إسبانيا. بناءً على المعلومات المستلمة، من المتوقع أن يحقق Teyame ما يقارب $34 مليون من الإيرادات و $4.2 مليون من EBITDA للعام المالي 2025. يهدف الدمج إلى إنشاء منصة عالمية لإشراك المرضى مدعومة بالذكاء الاصطناعي من خلال دمج Gen AI Agentic من Teyame، والأتمتة متعددة اللغات، والتحليلات مع أنظمة HCTI الإكلينيكية ومنتجات QuantumNexis.

الآثار المتوقعة تتضمن توسيع نطاق الوصول الدولي (أوروبا، LATAM، MENA، APAC)، البيع المتبادل إلى شبكة المستشفيات والعيادات لدى HCTI، تحسين سير العمل الرقمي للصحة العقلية، وتكامل أقوى من الواجهة الأمامية إلى الخلفية الإكلينيكية. تظل LOI غير ملزمة وتخضع لإتمامها.

Healthcare Triangle (纳斯达克: HCTI) 已签署一份非绑定的意向书,拟收购西班牙公司 Teyame.AI 的资产,这是一款由 AI 驱动的全渠道客户体验平台。根据所收到的信息,Teyame 预计在 2025 财年实现约 $34 百万美元 的收入和 $4.2 百万美元 的 EBITDA。此次合并旨在通过将 Teyame 的 Agentic Gen AI、多语言自动化和分析能力,与 HCTI 的临床系统和 QuantumNexis 产品结合,打造全球化的 AI 驱动的患者参与平台。

预期影响 包括扩大国际覆盖范围(欧洲、LATAM、MENA、APAC)、在 HCTI 的医院和诊所网络中实现交叉销售、改善数字化精神健康工作流程,以及前端到后端临床集成的更紧密协同。LOI 仍为非绑定,需待完成。

Positive
  • Projected incremental revenue of $34M for fiscal 2025
  • Projected incremental EBITDA of $4.2M for fiscal 2025
  • Immediate cross-selling access to HCTI's hospital and clinic network
  • Expansion into Europe, Latin America, Middle East and Asia-Pacific
Negative
  • LOI is non-binding, so transaction completion is uncertain
  • Financial projections are based on information provided by Teyame and are provisional

Insights

Non-binding LOI to buy Teyame.AI cites ~$34M revenue and $4.2M EBITDA for fiscal 2025; transaction would add AI CX capabilities.

The LOI is non-binding but discloses concrete financials: Teyame is expected to produce approximately $34 million of incremental annual revenue and $4.2 million of incremental EBITDA for fiscal 2025. If completed, the deal would combine HCTI's healthcare technology stack with Teyame's AI-powered omnichannel customer experience platform and multilingual capabilities, creating a front-end engagement layer tied to back-end clinical systems.

Key dependencies and risks are explicit: the announcement is an LOI (no binding terms disclosed) and the stated financials come from information received from Teyame. Material items to watch are completion of a binding agreement, the disclosed $34M/$4.2M financials' verification during due diligence, and any integration steps with QuantumNexis products like Ziloy and Ezovion; monitor these milestones across the near term, especially progress toward a binding agreement following the Oct. 9, 2025 announcement.

PLEASANTON, Calif., Oct. 9, 2025 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announced it has signed a non-binding Letter of Intent (LOI) to acquire the assets of Teyame.AI LLC ("Teyame"), a Spain-based leader in AI-powered omnichannel customer experience (CX) solutions. This acquisition would position the Company as a global force in AI-powered customer and patient engagement.

The strategic acquisition would address a critical gap in healthcare: the disconnect between advanced clinical systems and meaningful patient interaction. By combining HCTI's deep healthcare technology expertise with Teyame's proven AI automation customer engagement platform, an integrated ecosystem would be created where every patient touchpoint would become intelligent, personalized, and outcome-focused.

Based on financial information the Company has received from Teyame, the Company expects Teyame to generate approximately $34 million in incremental annual revenue and $4.2 million in incremental EBITDA for fiscal year 2025. The acquisition would represent a pivotal moment in HCTI's evolution from healthcare IT provider to comprehensive digital health innovator and could significantly enhance HCTI's financial performance and shareholder value.

"The transaction would bring real world lived experience of Agentic Gen AI, in addition to material revenues and profitability to HCTI" added David Ayanoglou, Chief Financial Officer of HCTI" 

Proven AI Innovation and Customer Engagement Meets Healthcare Expertise

Madrid-headquartered Teyame.AI has built a sophisticated platform that seamlessly blends artificial intelligence with human expertise, currently serving banking and insurance clients while piloting breakthrough healthcare applications. The company's technology stack includes advanced chatbot automation, multilingual patient engagement tools, and real-time analytics… capabilities that become exponentially more powerful when integrated with HCTI's clinical systems.

Key highlights of Teyame's innovation include:

  • Integration of Agentic Generative AI (Gen AI) into core operations.
  • Advanced AI-human collaboration models to drive efficiency.
  • Pilots of AI-powered healthcare services, such as appointment confirmations and multilingual patient engagement.
  • Evolution into a digital-first, AI-powered global CX provider.

Building a Comprehensive Healthcare Engagement Platform

Once completed, this acquisition would create a global, digital-first patient engagement platform that combines HCTI's healthcare technology expertise with Teyame's advanced automation capabilities.

Key anticipated synergies include:

  • Integration with QuantumNexis (HCTI Subsidiary) Products
    • Teyame's omnichannel platform will seamlessly integrate with Ziloy, QuantumNexis' advanced AI engine, and Ezovion, a comprehensive EHR/HIS solution.
    • This combination will deliver a front-end, patient engagement platform tightly connected to back-end clinical systems.
  • Enhanced Patient Engagement:
    • Expansion of Ziloy's digital mental health programs using chatbot-led, AI-driven workflows.
    • Personalized care journeys and outreach based on real-time patient data.
  • Global Market Reach:
    • Expansion into Europe, Latin America, Middle East and Asia-Pacific leveraging Teyame's multilingual, scalable platform.
  • AI-Driven Personalization:
    • Intelligent automation for treatment plans, chronic care workflows, and targeted outreach, improving patient outcomes and hospital efficiency.
  • Cross-Selling Opportunities:
    • Immediate ability to introduce Teyame's capabilities to HCTI's extensive hospital and clinic network.
  • Acquisition of High-Quality Talent:
    • Strengthening HCTI's innovation team with Teyame's domain experts in AI, CX, and automation.

"This strategic acquisition would expand our reach into international markets and provide our customers with cutting-edge Gen AI solutions," said Sujatha Ramesh, Chief Operating Officer of HCTI. "By integrating Teyame's technology and services with HCTI's healthcare offerings, we could create a next-generation, AI-powered ecosystem for patients, providers, and healthcare organizations." 

Strategic Growth Alignment

This LOI could be a critical step in HCTI's broader strategy focused on:

  • AI-driven healthcare innovation.
  • Global SaaS platforms for patient engagement and care management.
  • Expansion into high-growth international markets through digital-first healthcare solutions.

By uniting human expertise with advanced AI, HCTI is accelerating its transformation into a global healthcare technology leader, creating measurable impact for patients, providers, and shareholders

About Healthcare Triangle

Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare organizations including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz™ and DataEz™. HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical & business performance optimization.

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995), and include, among others, statements regarding the consummation of the private placement, satisfaction of the customary closing conditions of the private placement and the use of the proceeds therefrom. Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors out lined in the company's annual report on form 10-K for the year ended December 31, 2024, on file with the Securities Exchange Commission (the "SEC") and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Investors:
1-800-617-9550  
ir@healthcaretriangle.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/healthcare-triangle-takes-bold-step-toward-ai-driven-future-with-the-signing-of-a-non-binding-loi-for-the-acquisition-of-teyameai-which-is-on-track-to-generate-34m-in-revenue-for-fiscal-year-2025-and-would-create-for-healthcare-302579295.html

SOURCE Healthcare Triangle, Inc.

FAQ

What did Healthcare Triangle (HCTI) announce on October 9, 2025?

HCTI announced a non-binding LOI to acquire assets of Teyame.AI, aiming to build a global AI-driven patient engagement platform.

How much revenue is Teyame.AI projected to generate for fiscal 2025 in the HCTI LOI?

Teyame is expected to generate approximately $34 million in revenue for fiscal 2025 based on information provided to HCTI.

What incremental EBITDA did HCTI cite for Teyame.AI for fiscal 2025?

HCTI cited approximately $4.2 million in incremental EBITDA for fiscal 2025.

How would the Teyame acquisition affect HCTI's product ecosystem (HCTI ticker: HCTI)?

The acquisition would integrate Teyame's omnichannel AI platform with QuantumNexis products to link front-end patient engagement to back-end clinical systems.

What international markets does HCTI expect to access through Teyame.AI?

HCTI expects to expand into Europe, Latin America, Middle East, and Asia-Pacific using Teyame's multilingual, scalable platform.

Is the Teyame.AI transaction final and guaranteed to close?

No. The announcement reflects a non-binding LOI and the transaction remains subject to due diligence and definitive agreements.
Healthcare Triangle Inc

NASDAQ:HCTI

HCTI Rankings

HCTI Latest News

HCTI Latest SEC Filings

HCTI Stock Data

16.10M
5.35M
8.22%
1.06%
17.27%
Health Information Services
Services-computer Integrated Systems Design
Link
United States
PLEASANTON